Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating

Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating.

Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence led the firm to use lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis.

Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating

The research firm pointed out some challenges for the pharmaceutical industry in 2025. These include sector-specific tariffs and Most-Favored-Nation prescription drug pricing, which aims to reduce prescription drug prices for Americans.

Despite these challenges, Wolfe Research has a positive outlook on Johnson & Johnson’s (NYSE:JNJ) growth prospects, especially from its Innovative Medicine division.

Johnson & Johnson (NYSE:JNJ) is an American multinational healthcare company that specializes in pharmaceuticals and medical technologies.

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: Top 10 Stocks Under $10 That Could Triple and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.